Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

NCT00418431 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Central Serous Chorioretinopathy

Interventions

DRUG: Intravitreal injection of Bevacizumab

Sponsor

Asociación para Evitar la Ceguera en México